FDA 483 - Dr. Reddy's Laboratories Limited (Chemical Tech Ops - III) - March 09, 2018

An FDA inspection conducted from March 5-9, 2018, at Dr. Reddy's Laboratories, Ltd., an Active Pharmaceutical Ingredients (API) manufacturer in Medak, Telengana, India, revealed significant deviations from Current Good Manufacturing Practices. The inspection report, known as an FDA Form 483, identified five key observations.

Foremost, the Quality Unit failed to ensure compliance with its own procedures, exhibiting systemic issues with managing Corrective and Preventive Actions (CAPAs) and complaint investigations, many of which were not closed within established timeframes or lacked proper justification for extensions. Data integrity concerns were also noted, with aborted sample sets lacking incident reports and backup data not being verified. Furthermore, the company lacked essential Quality Agreements with some starting material suppliers.

Building and equipment maintenance were also found deficient, with cracked ceilings and holes in manufacturing areas posing contamination risks. Quarantined API materials were improperly stored in active packaging cleanrooms, increasing the potential for mix-ups. Critically, several pieces of production equipment, despite being designated as "cleaned" and visually inspected, were found to contain foreign material or product residue, compromising product quality and safety. Dr. Reddy's Laboratories is required to thoroughly address these observations to ensure compliance with regulatory standards for pharmaceutical manufacturing.